Cargando…

Targeting cyclin-dependent kinases in sarcoma treatment: Current perspectives and future directions

Effective treatment of advanced/metastatic bone and soft tissue sarcomas still represents an unmet medical need. Recent advances in targeted therapies have highlighted the potential of cyclin-dependent kinases (CDK) inhibitors in several cancer types, including sarcomas. CDKs are master regulators o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Merlini, Alessandra, Pavese, Valeria, Manessi, Giulia, Rabino, Martina, Tolomeo, Francesco, Aliberti, Sandra, D’Ambrosio, Lorenzo, Grignani, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893281/ https://www.ncbi.nlm.nih.gov/pubmed/36741019 http://dx.doi.org/10.3389/fonc.2023.1095219

Ejemplares similares

EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing’s Sarcoma and Chondrosarcoma
por: Giordano, Giorgia, et al.
Publicado: (2021)

DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination
por: Merlini, Alessandra, et al.
Publicado: (2022)

Guideline-Based Follow-Up Outcomes in Patients With Gastrointestinal Stromal Tumor With Low Risk of Recurrence: A Report From the Italian Sarcoma Group
por: D’Ambrosio, Lorenzo, et al.
Publicado: (2023)

PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas—A Preclinical and Translational Study
por: Pignochino, Ymera, et al.
Publicado: (2021)

Cyclin-dependent kinase inhibitors in malignant hematopoiesis
por: Schirripa, Alessia, et al.
Publicado: (2022)

Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers
por: Lin, Z. Ping, et al.
Publicado: (2018)

How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience
por: Marchesi, Emanuela, et al.
Publicado: (2017)

New therapeutics for soft tissue sarcomas: Overview of current immunotherapy and future directions of soft tissue sarcomas
por: Seong, Gyuhee, et al.
Publicado: (2023)

Comprehensive Analysis of Role of Cyclin-Dependent Kinases Family Members in Colorectal Cancer
por: Guan, Liping, et al.
Publicado: (2022)

Cyclin-Dependent Kinase 6 Identified as the Target Protein in the Antitumor Activity of Tetrastigma hemsleyanum
por: Wei, Chaoguang, et al.
Publicado: (2022)

Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer
por: Howard, David, et al.
Publicado: (2022)

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
por: Pignochino, Ymera, et al.
Publicado: (2017)

Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.
por: Mesiano, Giulia, et al.
Publicado: (2018)

Review: Precise sarcoma patient-derived orthotopic xenograft (PDOX) mouse models enable identification of novel effective combination therapies with the cyclin-dependent kinase inhibitor palbociclib: A strategy for clinical application
por: Higuchi, Takashi, et al.
Publicado: (2022)

Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin’s lymphoma: a case report and review of the literature
por: Rota Scalabrini, Delia, et al.
Publicado: (2014)

Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia
por: Tibes, Raoul, et al.
Publicado: (2019)

Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer
por: Husinka, Lakyn, et al.
Publicado: (2020)

Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms
por: Wang, Bin, et al.
Publicado: (2021)

Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients
por: Vlenterie, Myrella, et al.
Publicado: (2016)

CD44 In Sarcomas: A Comprehensive Review and Future Perspectives
por: Fernández-Tabanera, Enrique, et al.
Publicado: (2022)

Cyclin-Dependent Kinase 5 Regulatory Subunit Associated Protein 3: Potential Functions and Implications for Development and Disease
por: Sheng, Linna, et al.
Publicado: (2021)

Investigating the Mechanism of Inhibition of Cyclin-Dependent Kinase 6 Inhibitory Potential by Selonsertib: Newer Insights Into Drug Repurposing
por: Baig, Mohammad Hassan, et al.
Publicado: (2022)

Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group
por: Racanelli, Dominga, et al.
Publicado: (2020)

Corrigendum: Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group
por: Racanelli, Dominga, et al.
Publicado: (2020)

Cyclin-Dependent Kinase Inhibitors Function as Potential Immune Regulators via Inducing Pyroptosis in Triple Negative Breast Cancer
por: Xu, Tao, et al.
Publicado: (2022)

Alpha–fetoprotein elevation in NUT midline carcinoma: a case report
por: D’Ambrosio, Lorenzo, et al.
Publicado: (2017)

Loss of the Cyclin-Dependent Kinase Inhibitor 1 in the Context of Brachyury-Mediated Phenotypic Plasticity Drives Tumor Resistance to Immune Attack
por: Hamilton, Duane H., et al.
Publicado: (2018)

The cyclin dependent kinase inhibitor p21(Cip1/Waf1) is a therapeutic target in high-risk neuroblastoma
por: Sorteberg, Agnes Luise, et al.
Publicado: (2022)

Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors
por: Rottier, Pauline, et al.
Publicado: (2023)

Activity of cytokine-induced killer cells against bone and soft tissue sarcoma
por: Sangiolo, Dario, et al.
Publicado: (2014)

Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck
por: Seront, Emmanuel, et al.
Publicado: (2019)

Role of the Combination of Cyclin-Dependent Kinase Inhibitors (CDKI) and Radiotherapy (RT) in the Treatment of Metastatic Breast Cancer (MBC): Advantages and Risks in Clinical Practice
por: Gagliano, Ambrogio, et al.
Publicado: (2021)

Case Report: Clinical Experience With Avelumab in Patients With Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in Europe
por: Fife, Kate, et al.
Publicado: (2021)

Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma
por: Fleuren, Emmy D. G., et al.
Publicado: (2023)

Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma
por: Li, Xiaoyang, et al.
Publicado: (2018)

Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST
por: Fiorino, Erika, et al.
Publicado: (2022)

Cyclin-dependent kinases
por: Malumbres, Marcos
Publicado: (2014)

A mutation-based radiomics signature predicts response to imatinib in Gastrointestinal Stromal Tumors (GIST)
por: Cappello, Giovanni, et al.
Publicado: (2023)

Comprehensive Analysis of Cyclin Family Gene Expression in Colon Cancer
por: Li, Jieling, et al.
Publicado: (2021)

Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions
por: Juric, Viktorija, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0tea84iiaouan626ipnopl9tmt